Narcolepsy: Pharmacology, Pathophysiology, and Genetics

Principles and Practice of Sleep Medicine

Volumn , Issue , 2005, Pages 761-779

  Mignot, Emmanuel ^a,b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c Stanford California and Cofounder   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350189115     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B0-72-160797-7/50071-9     Document Type: Chapter

References (158)

1. American Academy of Sleep Medicine International Classification of Sleep Disorders: Diagnostic and Coding Manual 2005, American Academy of Sleep Medicine, Westchester, Ill. 2nd ed.
2. Guilleminault C, Mignot E, Partinen M Controversies in the diagnosis of narcolepsy. Sleep 1994, 17(8 Suppl):S1-S6.
3. Aldrich MS The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 1996, 46:393-401.
4. Anic-Labat S, Guilleminault C, Kraemer HC, et al. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999, 22:77-87.
5. Overeem S, Mignot E, van Dijk JG, Lammers GJ Narcolepsy: Clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001, 18:78-105.
6. Dauvilliers Y, Billiard M, Montplaisir J Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003, 114:2000-2017.
7. Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
8. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
9. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
10. Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553-1562.
11. Kanbayashi T, Inoue Y, Chiba S, et al. CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002, 11:91-93.
12. Krahn LE, Pankratz VS, Oliver L, et al. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: Relationship to cataplexy and HLA DQB1*0602 status. Sleep 2002, 25:733-736.
13. Mignot E, Hayduk R, Black J, et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997, 20:1012-1020.
14. Mignot E, Lin L, Rogers W, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001, 68:686-699.
15. Hublin C, Kaprio J, Partinen M, et al. Daytime sleepiness in an adult, Finnish population. J Intern Med 1996, 239:417-423.
16. Mignot E Genetic and familial aspects of narcolepsy. Neurology 1998, 50(2 Suppl 1):S16-S22.
17. Solomon P Narcolepsy in Negroes. Dis Nerv Sys 1945, 6:179-183.
18. Tashiro T, Kambayashi T, Hishikawa Y An Epidemiological Study of Narcolepsy in Japanese. Proceedings of the 4th International Symposium on Narcolepsy; Tokyo June 16-17, 1994, 13.
19. Honda Y Census of narcolepsy, cataplexy and sleep life among teenagers in Fujisawa City. Sleep Res Online 1979, 8:191.
20. Lavie P, Peled R Narcolepsy is a rare disease in Israel. Sleep 1987, 10:608-609.
21. Geisler P, Croeleun F, Tracik F, Zulley J MSLT: Sleep latency in normals is age and sex related. J Seep Res 1998, 7(Suppl 2):99.
22. Bishop C, Rosenthal L, Helmus T, et al. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness. Sleep 1996, 19:727-730.
23. Carskadon MA, Wolfson A, Acebo C, et al. Adolescent sleep patterns, circadian timing, and sleepiness at a transition to early school days. Sleep 1998, 21:271-281.
24. Silber MH, Krahn LE, Olson EJ, Pankratz VS The epidemiology of narcolepsy in Olmsted County, Minnesota: A population-based study. Sleep 2002, 25:197-202.
25. Knecht CD, Oliver JE, Redding R, et al. Narcolepsy in a dog and a cat. J Am Vet Med Assoc 1973, 162:1052-1053.
26. Mitler MM, Boysen BG, Campbell L, Dement WC Narcolepsy-cataplexy in a female dog. Exp Neurol 1974, 45:332-340.
27. Baker TL, Foutz AS, McNerney V, et al. Canine model of narcolepsy: Genetic and developmental determinants. Exp Neurol 1982, 75:729-742.
28. Hungs M, Fan J, Lin L, et al. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res 2001, 11:531-539.
29. Mignot E, Nishino S, Sharp LH, et al. Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: Induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 1993, 13:1057-1064.
30. Nishino S, Mignot E Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997, 52:27-78.
31. Shelton J, Nishino S, Vaught J, et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995, 18:817-826.
32. Kushida CA, Baker TL, Dement WC Electroencephalographic correlates of cataplectic attacks in narcoleptic canines. Electroencephalogr Clin Neurophysiol 1985, 61:61-70.
33. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
34. Ripley B, Fujiki N, Okura M, et al. Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001, 8:525-534.
35. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999, 98:437-451.
36. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001, 30:345-354.
37. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: Molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 2003, 38:715-730.
38. Kisanuki YY, Chemelli RM, Sinton CM, et al. The role of orexin receptor type-1 (OXIR) in the regulation of sleep. Sleep 2000, 23(Suppl 2):A91.
39. Mignot E, Renaud A, Nishino S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: Evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl) 1993, 113:76-82.
40. Nishino S, Arrigoni J, Shelton J, et al. Desmethyl metabolites of serotonergic uptake inhibitors are more potent for suppressing canine cataplexy than their parent compounds. Sleep 1993, 16:706-712.
41. Wu MF, Gulyani SA, Yau E, et al. Locus coeruleus neurons: Cessation of activity during cataplexy. Neuroscience 1999, 91:1389-1399.
42. Wu MF, John J, Boehmer LB, et al. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J Physiol (Lond) 2004, 554:202-215.
43. Nishino S, Mao J, Sampathkumaran R, Shelton J Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998, 1:49-61.
44. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001, 21:1787-1794.
45. Mignot E, Nishino S, Guilleminault C, Dement WC Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994, 17:436-437.
46. Kanbayashi T, Honda K, Kodama T, et al. Implication of dopaminergic mechanisms in the wake-promoting effects of amphetamine: A study of D- and L-derivatives in canine narcolepsy. Neuroscience 2000, 99:651-659.
47. Miller JD, Farber J, Gatz P, et al. Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and walking in the rat. Brain Res 1983, 273:133-141.
48. Steinfels GF, Heym J, Strecker RE, Jacobs BL Behavioral correlates of dopaminergic unit activity in freely moving cats. Brain Res 1983, 258:217-228.
49. Castelli MP, Ferraro L, Mocci I, et al. Selective gamma-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid. J Neurochem 2003, 87:722-732.
50. Queva C, Bremner-Danielsen M, Edlund A, et al. Effects of GABA agonists on body temperature regulation in GABA(B[1])-/- mice. Br J Pharmacol 2003, 140:315-322.
51. Baker TL, Dement WC Canine narcolepsy-cataplexy syndrome: Evidence for an inherited monoaminergic-cholinergic imbalance. Brain Mechanisms of Sleep 1985, 199-233. Raven Press, New York. D.J. McGinty, R. Drucker-Colin, A. Morrison, P.L. Parmeggiani (Eds.).
52. Aldrich MS The neurobiology of narcolepsy-cataplexy. Prog Neurobiol 1993, 41:533-541.
53. Miller JD, Faull KF, Bowersox SS, Dement WC CNS monoamines and their metabolites in canine narcolepsy: A replication study. Brain Res 1990, 509:169-171.
54. KilduffTS, Bowersox SS, Kaitin KI, et al. Muscarinic cholinergic receptors and the canine model of narcolepsy. Sleep 1986, 9:102-106.
55. Kish SJ, Mamelak M, Slimovitch C, et al. Brain neurotransmitter changes in human narcolepsy. Neurology 1992, 42:229-234.
56. Aldrich MS, Hollingsworth Z, Penney JB Dopamine-receptor autoradiography of human narcoleptic brain. Neurology 1992, 42:410-415.
57. Aldrich MS, Prokopowicz G, Ockert K, et al. Neurochemical studies of human narcolepsy: Alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem. Sleep 1994, 17:598-608.
58. Bowersox SS, KilduffTS, Faull KF, et al. Brain dopamine receptor levels elevated in canine narcolepsy. Brain Res 1987, 402:44-48.
59. Khan N, Antonini A, Parkes D, et al. Striatal dopamine D2 receptors in patients with narcolepsy measured with PET and 11C-raclopride. Neurology 1994, 44:2102-2104.
60. Rinne JO, Hublin C, Partinen M, et al. Positron emission tomography study of human narcolepsy: No increase in striatal dopamine D2 receptors. Neurology 1995, 45:1735-1738.
61. MacFarlane JG, List SJ, Moldofsky H, et al. Dopamine D2 receptors quantified in vivo in human narcolepsy. Biol Psychiatry 1997, 41:305-310.
62. Faull KF, Guilleminault C, Berger PA, Barchas JD Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia. Ann Neurol 1983, 13:258-263.
63. Nishino S, Fujiki N, Ripley B, et al. Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. Neurosci Lett 2001, 313:125-128.
64. Nishino S, Tafti M, Reid MS, et al. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: Implication for the pathophysiology of canine narcolepsy. J Neurosci 1995, 15:4806-4814.
65. Reid MS, Nishino S, Tafti M, et al. Neuropharmacological characterization of basal forebrain cholinergic stimulated cataplexy in narcoleptic canines. Exp Neurol 1998, 151:89-104.
66. Reid MS, Tafti M, Nishino S, et al. Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcoleptic canine. Brain Res 1996, 733:83-100.
67. Westphal C Eigenthumliche mit Einschlafen verbundene Anfalle. Arch Psychiatr 1877, 7:631-635.
68. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328:1230-1235.
69. D'Alessandro R, Rinaldi R, Cristina E, et al. Prevalence of excessive daytime sleepiness an open epidemiological problem. Sleep 1995, 18:389-391.
70. Honda M, Honda Y, Uchida S, et al. Monozygotic twins incompletely concordant for narcolepsy. Biol Psychiatry 2001, 49:943-947.
71. Honda Y A monozygotic pair completely disordant for narcolepsy, with sleep deprivation as a possible precipitating factor. Sleep Biol Rhythms 2003, 1:147-149.
72. Dauvilliers Y, Maret S, Bassetti C, et al. A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology 2004, 62:2137.
73. Okun ML, Lin L, Pelin Z, et al. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002, 25:27-35.
74. Gill AW Idiopathic and traumatic narcolepsy. Lancet 1941, 1:474.
75. Guilleminault C, Faull KF, Miles L, van den Hoed J Posttraumatic excessive daytime sleepiness: A review of 20 patients. Neurology 1983, 33:1584-1589.
76. Lakford DA, Wellman JJ, O'Hara C Posttraumatic narcolepsy in mild to moderate closed head injury. Sleep 1994, 17(8 Suppl):S25-S28.
77. Orellana C, Villemin E, Tafti M, et al. Life events in the year preceding the onset of narcolepsy. Sleep 1994, 17(8 Suppl):S50-S53.
78. Roth B Narcolepsy and Hypersomnia 1980, Karger, Basel.
79. Mueller-Eckhardt G, Meier-Ewart K, Schiefer HG Is there an infectious origin of narcolepsy?. Lancet 1990, 335:424.
80. Dauvilliers Y, Carlander B, Molinari N, et al. Month of birth as a risk factor for narcolepsy. Sleep 2003, 26:663-665.
81. Dahmen N, Tonn P Season of birth effect in narcolepsy. Neurology 2003, 61:1016.
82. Honda Y, Asake A, Tanaka Y, Juji T Discrimination of narcolepsy by using genetic markers and HLA. Sleep Res 1983, 12:254.
83. Tuji T, Satake M, Honda Y, Doi Y HLA antigens in Japanese patients with narcolepsy: All the patients were DR2 positive. Tissue Antigens 1984, 24:316-319.
84. Mueller-Eckhardt G, Meier-Ewert K, Schendel DJ, et al. HLA and narcolepsy in a German population. Tissue Antigens 1986, 28:163-169.
85. Langdon N, Welsh KI, van Dam M, et al. Genetic markers in narcolepsy. Lancet 1984, 2:1178-1180.
86. Roth B, Nevsimalova S, Sonka K, et al. A study of the occurrence of HLA DR2 in 124 narcoleptics: Clinical aspects. Schweiz Arch Neurol Psychiatr 1988, 139(4):41-51.
87. Sachs C, Moller E The occurrence of HLA-DR2 in clinically established narcolepsy. Acta Neurol Scand 1987, 75:437-439.
88. Billiard M, Seignalet J, Besset A, Cadilhac J HLA-DR2 and narcolepsy. Sleep 1986, 9:149-152.
89. Poirier G, Montplaisir J, Decary F, et al. HLA antigens in narcolepsy and idiopathic central nervous system hypersomnolence. Sleep 1986, 9:153-158.
90. Mignot E, Tafti M, Dement WC, Grumet FC Narcolepsy and immunity. Adv Neuroimmunol 1995, 5:23-37.
91. Carlander B, Eliaou JF, Billiard M Autoimmune hypothesis in narcolepsy. Neurophysiol Clin 1993, 23:15-22.
92. Black JL, Krahn LE, Pankratz VS, Michael S Search for neuronspecific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602. Sleep 2002, 25:719-723.
93. Overeem S, Geleijins K, Garssen MP, et al. Screening for antiganglioside antibodies in hypocretin-deficient human narcolepsy. Neurosci Lett 2003, 341:13-16.
94. Thannickal TC, Siegel JM, Nienhuis R, Moore RY Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 2003, 13:340-351.
95. Kaufmann C, Schuld A, Pollamcher T, Auer DP Reduced cortical gray matter in narcolepsy: Preliminary findings with voxel-based morphometry. Neurology 2002, 58:1852-1855.
96. Draganski B, Geisler P, Hajak G, et al. Hypothalamic gray matter changes in narcoleptic patients. Nat Med 2002, 8:1186-1188.
97. Overeem S, Steens SC, Good CD, et al. Voxel-based morphometry in hypocretin-deficient narcolepsy. Sleep 2003, 26:44-46.
98. Mignot E, Lin X, Arrigoni J, et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 1994, 17(8 Suppl):S60-S67.
99. Mignot E, Kimura A, Lattermann A, et al. Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens 1997, 49:329-341.
100. Ellis MC, Hetisimer AH, Ruddy DA, et al. HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy. Immunogenetics 1997, 46:410-417.
101. Pelin Z, Guilleminault C, Risch N, et al. HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. U.S. Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 1998, 51:96-100.
102. Mignot E, Lin X, Kalil J, et al. DQB1-0602 (DQw1) is not present in most nonDR2 Caucasian narcoleptics. Sleep 1992, 15:415-422.
103. Nakayama J, Miura M, Honda M, et al. Linkage of human narcolepsy with HLA association to chromosome 4p13-q21. Genomics 2000, 65:84-86.
104. Hohjoh H, Terada N, Nakayama T, et al. Case-control study with narcoleptic patients and healthy controls who, like the patients, possess both HLA-DRB1*1501 and -DQB1*0602. Tissue Antigens 2001, 57:230-235.
105. Kato T, Honda M, Kuwata S, et al. Novel polymorphism in the promoter region of the tumor necrosis factor alpha gene: No association with narcolepsy. Am J Med Genet 1999, 88:301-304.
106. Wieczorek S, Gencik M, Rujescu D, et al. TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 2003, 61:437-442.
107. Dauvilliers Y, Neidhart E, Billiard M, Fafti M Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modfainil. Pharmacogenom J 2002, 2:65-68.
108. Dauvilliers Y, Neidhart E, Lecendreux M, et al. MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 2001, 6:367-372.
109. Hungs M, Lin L, Okun M, Mignot E Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy. Neurology 2001, 57:1893-1895.
110. Olafsdottir BR, Rye DB, Scammell TE, et al. Polymorphisms in hypocretin/orexin pathway genes and narcolepsy. Neurology 2001, 57:1896-1899.
111. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253-2258.
112. Evans RW Complications of lumbar puncture. Neurol Clin 1998, 16:83-105.
113. Dalal MA, Schuld A, Pollmacher T Undetectable CSF level of orexin A (hypocretin-1) in a HLA-DR2 negative patient with narcolepsy-cataplexy. J Sleep Res 2002, 11:273.
114. Hecht M, Lin L, Kushida CA, et al. Immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin deficiency/narcolepsy. Sleep 2003, 26:809-810.
115. Kubota H, Kanbayashi T, Tanabe Y, et al. Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children. Sleep 2003, 26:555-557.
116. Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol Psychiatry 2003, 54:96-104.
117. von Economo C Encephalitis Lethargica: Its Sequelae and Treatment 1931, Oxford University Press, London.
118. von Economo C Sleep as a problem of localization. J Nerv Ment Dis 1930, 71:249-259.
119. Daniels LE Narcolepsy. Medicine (Baltimore) 1934, 13(1):1-122.
120. Mignot E A hundred years of narcolepsy research. Arch Ital Biol 2001, 139:207-220.
121. Symonds CP Narcolepsy as a symptom of encephalitis lethargica. Lancet 1926, 12:1214-1215.
122. Adie WJ Idiopathic narcolepsy: A disease sui generis; with remarks on the mechanism of sleep. Brain 1926, 49:257-306.
123. Aldrich MS, Naylor MW Narcolepsy associated with lesions of the diencephalon. Neurology 1989, 39:1505-1508.
124. Mignot E, Chen W, Black J On the value of measuring CSF hypocretin-1 in diagnosing narcolepsy. Sleep 2003, 26:646-649.
125. Arii J, Kanbayashi T, Tanabe Y, et al. A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor. Neurology 2001, 56:1775-1776.
126. Dempsey OJ, McGeoch P, De Silva RN, Douglas NJ Acquired narcolepsy in an acromegalic patient who underwent pituitary irradiation. Neurology 2003, 61:537-540.
127. Kato T, Kanbayashi T, Yamamoto K, et al. Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions. Intern Med 2003, 42:743-745.
128. Kubota H, Kanbayashi T, Tanabe Y, et al. A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid. J Child Neurol 2002, 17:537-539.
129. Scammell TE, Nishino S, Mignot E, Saper CB Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 2001, 56:1751-1753.
130. Overeem S, van Hilten JJ, Ripley B, et al. Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology 2002, 58:498-499.
131. Nelson GB, Hahn JS Stimulus-induced drop episodes in Coffin-Lowry syndrome. Pediatrics 2003, 111:197-202.
132. Parkes JD Genetic factors in human sleep disorders with special reference to Norrie disease, Prader-Willi syndrome and Moebius syndrome. J Sleep Res 1999, 8(Suppl 1):14-22.
133. Kanbayashi T, Abe M, Fujimoto S, et al. Hypocretin deficiency in Niemann-Pick type C with cataplexy. Neuropediatrics 2003, 34:52-53.
134. Vankova J, Stepanova I, Jech R, et al. Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep 2003, 26:427-430.
135. Martinez-Rodriguez JE, Lin L, Iranzo A, et al. Decreased hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep 2003, 26:287-290.
136. Katz ES, McGrath S, Marcus CL Late-onset central hypoventilation with hypothalamic dysfunction: A distinct clinical syndrome. Pediatr Pulmonol 2000, 29:62-68.
137. Fujiki N, Yoshida Y, Ripley B, et al. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport 2001, 12:993-997.
138. Zeitzer JM, Buckmaster CL, Parker KJ, et al. Circadian and homeostatic regulation of hypocretin in a primate model: Implications for the consolidation of wakefulness. J Neurosci 2003, 23:3555-3560.
139. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001, 435:6-25.
140. Hungs M, Mignot E Hypocretin/orexin, sleep and narcolepsy. Bioessays 2001, 23:397-408.
141. Taheri S, Zeitzer JM, Mignot E The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 2002, 25:283-313.
142. Beuckmann CT, Yanagisawa M Orexins: From neuropeptides to energy homeostasis and sleep/wake regulation. J Mol Med 2002, 80:329-342.
143. Mignot E, Taheri S, Nishino S Sleeping with the hypothalamus: Emerging therapeutic targets for sleep disorders. Nat Neurosci 2002, 5(Suppl):1071-1075.
144. Lin JS, Hou Y, Sakai K, Jouvet M Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat. J Neurosci 1996, 16:1523-1537.
145. Schuld A, Hebebrand J, Geller F, Pollmacher T Increased body-mass index in patients with narcolepsy. Lancet 2000, 355:1274-1275.
146. Kok SW, Overeem S, Visscher TL, et al. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 2003, 11:1147-1154.
147. Yamanaka A, Beuckmann CT, Willie JT, et al. Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 2003, 38:701-713.
148. John J, Wu MF, Siegel MJ Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 2000, 3:23-28.
149. Nishino S, Fujiki N, Yoshida Y, Mignot E The effects of hypocretin-1 in hypocretin receptor-2 mutated and hypocretin deficient narcoleptic dogs. Sleep 2003, 26(Suppl):A287.
150. Yoshida Y, Fujiki N, Maki RA, et al. Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats. Neurosci Lett 2003, 346:182-186.
151. Schatzberg SJ, Barrett J, Cutter K, et al. Case study: Effect of hypocretin replacement therapy in a 3-year-old weimaraner with narcolepsy. J Vet Intern Med 2004, 18:586-588.
152. Hecht M, Lin L, Kushida CA, et al. Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficient narcolepsy. Sleep 2003, 26:809-810.
153. Lecendreux M, Maret S, Bassetti C, et al. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003, 12:1-2.
154. Fernandez-Vina MA, Gao XJ, Moraes ME, et al. Alleles at four HLA class II loci determined by oligonucleotide hybridization and their associations in five ethnic groups. Immunogenetics 1991, 34:299-312.
155. Voderholzer U, Riemann D, Gann H, et al. Transient total sleep loss in cerebral Whipple's disease: A longitudinal study. J Sleep Res 2002, 11:321-329.
156. Marcus CL, Trescher WH, Halbower AC, Lutz J Secondary narcolepsy in children with brain tumors. Sleep 2002, 25:435-439.
157. Marcus CL, Mignot E Letter to the editor regarding our previous publication: "Secondary narcolepsy in children with brain tumors," SLEEP 2002;25:435-439. Sleep 2003, 26:228.
158. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1996. Tissue Antigens 1997, 49:297-321.